keyword
MENU ▼
Read by QxMD icon Read
search

Bone scans in prostate cancer

keyword
https://www.readbyqxmd.com/read/28806238/68ga-psma-uptake-in-combined-hepatocellular-cholangiocarcinoma-with-skeletal-metastases
#1
Ramin Alipour, Sandeep Gupta, Scott Trethewey
Ga-PSMA PET is a rapidly evolving imaging modality for whole-body staging of prostate cancer. We report a case of a 70-year-old man with mildly elevated prostate-specific antigen (8.1 μg/L) and clinical suspicion of prostate cancer (osteoblastic metastases on radionuclide bone scan) who was referred for Ga-PSMA PET/CT for primary staging. Multiple Ga-PSMA-avid skeletal foci, mostly associated with lytic changes on low-dose CT, as well as hepatic foci of avid Ga-PSMA uptake, were identified. No abnormal focus of avid Ga-PSMA uptake was identified in the prostate...
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28780775/editorial-comment-to-bone-scan-index-a-new-biomarker-of-bone-metastasis-in-patients-with-prostate-cancer
#2
Shinichi Sakamoto
No abstract text is available yet for this article.
August 6, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28762288/the-phytological-future-of-prostate-cancer-staging-prostate-specific-membrane-antigen-positron-emission-tomography-and-the-dandelion-theory
#3
Niranjan J Sathianathen, Nicolas Geurts, Rajesh Nair, Nathan Lawrentschuk, Declan G Murphy, Alastair D Lamb
PSMA-PET is changing how we stage prostate cancer, both in the primary setting and with relapse after treatment. It allows us to identify lesions in the bones and lymph nodes that were not previously visible on conventional imaging with bone scan and CT/MRI. In this Special Report we review the 'state of the art' for PSMA imaging and discuss the implications for treatment decisions in prostate cancer. We liken early high risk or metastatic prostate to a common phytological problem: the dandelion. In this analogous situation, we consider the additional evidence needed for us to start plucking out the original dandelion and for us to focus attention on killing the seeded weeds that are identifiable elsewhere in the lawn...
August 1, 2017: Future Oncology
https://www.readbyqxmd.com/read/28760556/bone-scan-index-is-an-independent-predictor-for-time-to-castration-resistant-prostate-cancer-in-newly-diagnosed-prostate-cancer-a-prospective-study
#4
Helle D Zacho, Michael Gade, Jesper C Mortensen, Henrik Bertelsen, Ren K Boldsen, Tamás Barsi, Lars J Petersen
OBJECTIVE: To prospectively determine the prognostic value of the bone scan index (BSI) for time to development of castration-resistant prostate cancer (CRPC) in consecutive, hormone-naïve patients with newly diagnosed prostate cancer. PATIENTS AND METHODS: Eligible patients participated in a prospective, observational, multi-center study of the value of bone scintigraphy (BS) at staging. BSI was determined using the EXINIBone(BSI)-software in 208 consecutive patients undergoing androgen deprivation therapy...
July 28, 2017: Urology
https://www.readbyqxmd.com/read/28758969/assessment-of-bone-metastases-in-patients-with-prostate-cancer-a-comparison-between-99m-tc-bone-scintigraphy-and-68-ga-ga-psma-pet-ct
#5
Lena Thomas, Caroline Balmus, Hojjat Ahmadzadehfar, Markus Essler, Holger Strunk, Ralph A Bundschuh
PURPOSE: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. METHODS: Thirty patients with bone metastases originating from prostate cancer were examined by (99m)Tc-MDP bone scan and (68)Ga-PSMA-PET/CT within an average of 21 days...
July 31, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28755965/reply-by-the-authors-to-the-editorial-on-zacho-hd-gade-m-mortensen-jc-bertelsen-h-boldsen-sk-petersen-lj-bone-scan-index-is-an-independent-predictor-for-time-to-castration-resistant-prostate-cancer-in-newly-diagnosed-prostate-cancer-a-prospective-study-urology
#6
https://www.readbyqxmd.com/read/28753806/-68-ga-labeled-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-computed-tomography-for-prostate-cancer-a-systematic-review-and-meta-analysis
#7
REVIEW
Finn E von Eyben, Maria Picchio, Rie von Eyben, Handoo Rhee, Glenn Bauman
CONTEXT: (68)Gallium prostate-specific membrane antigen (PSMA) ligand (68)Ga-HBED-CC-PSMA ((68)Ga-PSMA) is a promising radiotracer for positron emission tomography (PET)/computed tomography (CT) of prostate cancer. OBJECTIVE: To conduct a meta-analysis to evaluate detection rate, diagnostic test accuracy, and adverse effects of (68)Ga-PSMA PET/CT or PET/magnetic resonance imaging (MRI) for staging of prostate cancer and for restaging of rising prostate-specific antigen (PSA) after initial treatment...
November 15, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28753792/interrogating-metastatic-prostate-cancer-treatment-switch-decisions-a-multi-institutional-survey
#8
David Lorente, Praful Ravi, Niven Mehra, Carmel Pezaro, Aurelius Omlin, Alexa Gilman, Miguel Miranda, Pasquale Rescigno, Michael Kolinsky, Nuria Porta, Diletta Bianchini, Nina Tunariu, Raquel Perez, Joaquin Mateo, Heather Payne, Leon Terstappen, Maarten IJzerman, Emma Hall, Johann de Bono
BACKGROUND: Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic biomarkers are inconsistently utilized. Circulating tumor cell (CTC) counts can inform prognosis and response, but are not routinely used. OBJECTIVE: To evaluate the use of biomarkers and trends in clinical decision-making in current mCRPC treatment...
October 10, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28753787/in-men-with-castration-resistant-prostate-cancer-visceral-metastases-predict-shorter-overall-survival-what-predicts-visceral-metastases-results-from-the-search-database
#9
Colette A Whitney, Lauren E Howard, Edwin M Posadas, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Stephen J Freedland
BACKGROUND: Although visceral metastases (VMs) are widely recognized to portend worse prognoses compared with bone and lymph metastases in men with metastatic castration-resistant prostate cancer (mCRPC), little is known about what predicts VMs and the extent to which men with VMs do worse. OBJECTIVE: To determine whether men with VMs at initial mCRPC diagnosis have worse overall survival (OS) and identify predictors of VMs. DESIGN, SETTING, AND PARTICIPANTS: We analyzed 494 men diagnosed with castration-resistant prostate cancer post-1999 and no known metastases from five Veterans Affairs hospitals of the Shared Equal Access Regional Cancer Hospital (SEARCH) database who later developed metastases...
August 29, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28725594/weekly-ascorbic-acid-infusion-in-castration-resistant-prostate-cancer-patients-a-single-arm-phase-ii-trial
#10
Torben K Nielsen, Martin Højgaard, Jon T Andersen, Niklas Rye Jørgensen, Bo Zerahn, Bent Kristensen, Trine Henriksen, Jens Lykkesfeldt, Kári J Mikines, Henrik E Poulsen
BACKGROUND: Ascorbic acid (AA) has in vivo cytotoxic properties at concentrations that can only be achieved through intravenous (IV) administration in humans. Treatment with intravenous AA is widely and increasingly used in complementary medicine despite a lack of clinical evidence for the efficacy of this treatment. METHODS: This non-comparative, single-center, phase II trial included patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) from an outpatient clinic to evaluate the efficacy and safety of IV AA therapy...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28723521/bone-scan-index-and-progression-free-survival-data-for-progressive-metastatic-castration-resistant-prostate-cancer-patients-who-received-odm-201-in-the-arades-multicentre-study
#11
Mariana Reza, Robert Jones, John Aspegren, Christophe Massard, Leena Mattila, Mika Mustonen, Per Wollmer, Elin Trägårdh, Eva Bondesson, Lars Edenbrandt, Karim Fizazi, Anders Bjartell
BACKGROUND: ODM-201, a new-generation androgen receptor inhibitor, has shown clinical efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess changes in bone as a measurement of treatment response. The Bone Scan Index (BSI) reflects the percentage of skeletal mass a given tumour affects. OBJECTIVE: To evaluate the predictive value of the BSI in metastatic castration-resistant PCa (mCRPC) patients undergoing treatment with ODM-201...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723520/bone-scan-index-as-an-imaging-biomarker-in-metastatic-castration-resistant-prostate-cancer-a-multicentre-study-based-on-patients-treated-with-abiraterone-acetate-zytiga-in-clinical-practice
#12
Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck-Lissbrant, Jan-Erik Damber, Anders Widmark, Camilla Thellenberg-Karlsson, Lars Budäus, Thomas Steuber, Till Eichenauer, Per Wollmer, Lars Edenbrandt, Elin Trägårdh, Anders Bjartell
BACKGROUND: Abiraterone acetate (AA) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. To measure treatment response accurately in bone, quantitative methods are needed. The Bone Scan Index (BSI), a prognostic imaging biomarker, reflects the tumour burden in bone as a percentage of the total skeletal mass calculated from bone scintigraphy. OBJECTIVE: To evaluate the value of BSI as a biomarker for outcome evaluation in mCRPC patients on treatment with AA according to clinical routine...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28721304/imaging-features-of-paget-s-disease-on-11-c-choline-pet-ct
#13
Cameron E Leitch, Ajit H Goenka, Benjamin M Howe, Stephen M Broski
The purpose of this study was to investigate the appearance of Paget's disease (PD) on (11)C choline PET/CT and correlate these findings to serum alkaline phosphatase (ALP) level and skeletal scintigraphy. With IRB approval, our institutional (11)C choline PET/CT database (9/2005-6/2015) was searched for patients with PD. Site of osseous involvement, CT appearance, and multiple semi-quantitative measures were measured and correlated with ALP and degree of uptake on bone scan. Our search identified 10 males (mean age 79...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28719448/biopsy-proven-diffuse-mediastinal-prostate-cancer-metastases-negative-on-18f-fluorocholine-diagnosed-on-68ga-psma-and-18f-psma-pet-ct
#14
Guillaume Chaussé, Tamim Niazi, Gad Solomon Abikhzer, Stephan Michael Probst
A 72-year-old man with prostate cancer (stage T3b, Gleason score 7) treated by radical prostatectomy was found to have biochemical failure (prostate-specific antigen 8.5 ng/mL) and a suspicious growing nodularity at the left prostate bed on MRI. F-fluorocholine PET/CT failed to demonstrate any site of uptake suggestive of malignancy. A bone scan did exclude bone metastases. Ga-PSMA PET/CT revealed various positive lymph nodes in the supraclavicular, mediastinal, and hilar regions. This was confirmed on F-DCFPyl PET/CT, with the addition of a suspicious right axillary lymph node...
July 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28693433/prospective-evaluation-of-computer-assisted-analysis-of-skeletal-lesions-for-the-staging-of-prostate-cancer
#15
Lars J Petersen, Jesper C Mortensen, Henrik Bertelsen, Helle D Zacho
BACKGROUND: The purpose of this study was to compare the agreement of the bone scan index (BSI) using EXINI Bone(BSI) versus experts' readings in the initial staging for bone metastasis in prostate cancer. In addition, the diagnostic outcome was assessed in a large subset of patients where a true reference for metastases could be determined based on clinical and biochemical follow-up and/or supplementary imaging. METHODS: A total of 342 patients had a bone scintigraphy as part of routine staging for prostate cancer...
July 10, 2017: BMC Medical Imaging
https://www.readbyqxmd.com/read/28678671/temporal-subtraction-of-serial-ct-images-with-large-deformation-diffeomorphic-metric-mapping-in-the-identification-of-bone-metastases
#16
Ryo Sakamoto, Masahiro Yakami, Koji Fujimoto, Keita Nakagomi, Takeshi Kubo, Yutaka Emoto, Thai Akasaka, Gakuto Aoyama, Hiroyuki Yamamoto, Michael I Miller, Susumu Mori, Kaori Togashi
Purpose To determine the improvement of radiologist efficiency and performance in the detection of bone metastases at serial follow-up computed tomography (CT) by using a temporal subtraction (TS) technique based on an advanced nonrigid image registration algorithm. Materials and Methods This retrospective study was approved by the institutional review board, and informed consent was waived. CT image pairs (previous and current scans of the torso) in 60 patients with cancer (primary lesion location: prostate, n = 14; breast, n = 16; lung, n = 20; liver, n = 10) were included...
July 3, 2017: Radiology
https://www.readbyqxmd.com/read/28654366/quantitative-assessment-of-early-18-f-sodium-fluoride-positron-emission-tomography-computed-tomography-response-to-treatment-in-men-with-metastatic-prostate-cancer-to-bone
#17
Stephanie A Harmon, Timothy Perk, Christie Lin, Jens Eickhoff, Peter L Choyke, William L Dahut, Andrea B Apolo, John L Humm, Steven M Larson, Michael J Morris, Glenn Liu, Robert Jeraj
Purpose [(18)F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) is a promising radiotracer for quantitative assessment of bone metastases. This study assesses changes in early NaF PET/CT response measures in metastatic prostate cancer for correlation to clinical outcomes. Patients and Methods Fifty-six patients with metastatic castration-resistant prostate cancer (mCRPC) with osseous metastases had NaF PET/CT scans performed at baseline and after three cycles of chemotherapy (n = 16) or androgen receptor pathway inhibitors (n = 40)...
June 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28646594/prevalence-and-prognosis-of-low-volume-oligorecurrent-hormone-sensitive-prostate-cancer-amenable-to-lesion-ablative-therapy
#18
Aurélie De Bruycker, Bieke Lambert, Tom Claeys, Louke Delrue, Chamberlain Mbah, Gert De Meerleer, Geert Villeirs, Filip De Vos, Kathia De Man, Karel Decaestecker, Valérie Fonteyne, Nicolaas Lumen, Filip Ameye, Ignace Billiet, Steven Joniau, Friedl Vanhaverbeke, Wim Duthoy, Piet Ost
OBJECTIVES: To describe the anatomical patterns of PCa recurrence following primary therapy and investigate if patients with low-volume disease have a better prognosis as compared to their counterparts. MATERIAL AND METHODS: Patients eligible for a F18-choline PET-CT were entered in a prospective cohort study. Eligible patients had an asymptomatic biochemical recurrence following primary PCa treatment and testosterone levels >50 ng/ml. The number of lesions were counted per scan...
June 24, 2017: BJU International
https://www.readbyqxmd.com/read/28623852/frusemide-aids-diagnostic-interpretation-of-68-ga-psma-positron-emission-tomography-ct-in-men-with-prostate-cancer
#19
Niall Fennessy, Jonathan Lee, Jane Shin, Bao Ho, Syed Aman Ali, Royce Paschkewitz, Louise Emmett
INTRODUCTION: (68) Ga-PSMA positron emission tomography-computed tomography (PET/CT) is useful for both staging and assessment of biochemical relapse in men with prostate cancer. Renal excretion of (68) Ga-PSMA can lead to difficulties in scan interpretation, particularly in the pelvis. We evaluated if intravenous Frusemide at the time of (68) Ga-PSMA injection reduces excreted activity artefact and improves diagnostic certainty. METHODS: Sixty-two men with prostate cancer undergoing clinically indicated (68) Ga-PSMA PET/CT were prospectively included, 30 men receiving Frusemide at the time of radiotracer injection...
June 17, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28613198/lu-177-psma-617-prostate-specific-membrane-antigen-inhibitor-therapy-in-patients-with-castration-resistant-prostate-cancer-stability-bio-distribution-and-dosimetry
#20
Levent Kabasakal, Türkay Toklu, Nami Yeyin, Emre Demirci, Mohammad Abuqbeitah, Meltem Ocak, Aslan Aygün, Emre Karayel, Hüseyin Pehlivanoğlu, Nalan Alan Selçuk
OBJECTIVE: The aim of the study was to estimate the radiation-absorbed doses and to study the in vivo and in vitro stability as well as pharmacokinetic characteristics of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617. METHODS: For this purpose, 7 patients who underwent Lu-177-PSMA therapy were included into the study. The injected Lu-177-PSMA-617 activity ranged from 3.6 to 7.4 GBq with a mean of 5.2±1.8 GBq. The stability of radiotracer in saline was calculated up to 48 h...
June 1, 2017: Molecular Imaging and Radionuclide Therapy
keyword
keyword
63986
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"